
Eris Lifesciences Ltd
NSE:ERIS

During the last 3 months Eris Lifesciences Ltd insiders have not bought any shares, and have not sold any shares. The stock price has increased by 3% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nse/eris/vs/indx/bsesn">open performance analysis).
The last transaction was made on
Aug 17, 2023
by
Sabyasachi Sharma
(Vice President)
, who
sold
1.6m INR
worth of ERIS shares.
During the last 3 months Eris Lifesciences Ltd insiders have not bought any shares, and have not sold any shares. The stock price has increased by 3% over this period ( loading = false, 5000)" href="https://www.alphaspread.com/comparison/nse/eris/vs/indx/bsesn">open performance analysis).
The last transaction was made on
Aug 17, 2023
by
Sabyasachi Sharma
(Vice President)
, who
sold
1.6m INR
worth of ERIS shares.
Eris Lifesciences Ltd
Glance View
Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue. The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

What is Insider Trading?
Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.